On August 7, ResMed fell 8.41% in pre-market trading, trading at $204.0/share, with turnover of $29,400. The decline followed the company's fiscal Q4 earnings release, where results beat estimates but slowing top-line momentum triggered selling pressure.

ResMed reported adjusted EPS of $2.95, exceeding the consensus estimate of $2.89, while revenue of $1.46 billion matched expectations, representing 8.1% year-over-year growth. However, revenue growth has decelerated from prior double-digit levels to approximately 8%, creating a notable gap with the company's three-year EPS compound annual growth rate of 19%. The market views this divergence as a signal of potentially limited future growth runway. Additionally, approximately $41.9 million in charges related to the Astral field safety notice weighed on GAAP profit margins, further dampening sentiment.

The company simultaneously announced plans to return over $1.85 billion to shareholders in fiscal 2027 and raised its quarterly dividend 10% to $0.66 per share. Despite these shareholder-friendly measures, concerns over structural growth deceleration dominated trading activity.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)